2021-09-10 |
118 |
Notice of Service |
Amended Invalidity Contentions regarding U.S. Patent No. 6,911,461 filed by Annora Pharma Private Limited, … 12 September 2023
1:20-cv-00987
835 Patent - Abbreviated New Drug Application(ANDA)
None |
External link to document |
2021-10-12 |
128 |
Notice to Take Deposition |
Invalidity
Contentions Regarding U.S. Patent No. 6,911,461.
4. The term “Your ANDA…assessment, analysis, or opinion regarding the ’461 Patent, including
the validity and enforceability thereof…18. Your knowledge of prior art to the ’461 Patent including Your knowledge of the
references cited…Your Notice
Letter to UCB regarding the ’461 Patent, including but not limited to the entire “detailed…ANDA Product prior to expiration
of the ’461 Patent and the final resolution of this litigation, including |
External link to document |
2022-01-11 |
188 |
Letter |
analyses of the validity
of U.S. Patent No. 6,911,461 (“the ’461 Patent”). UCB respectfully requests that…validity of the ’461 Patent—the only issue raised with respect to the only patent at issue in
this lawsuit—are…stipulated to infringement of all claims of the ’461
Patent, which covers Briviact and its active ingredient… scope, validity, or enforceability of the ’461 Patent.” Ex. B at 11. After an agreed-upon extension
…in this litigation is the
validity of the ’461 Patent. See D.I. 57 at 28–29. There can be no reasonable |
External link to document |
2022-02-03 |
194 |
Consent Judgment - Proposed |
) the term “Licensed Patent” shall mean United States
Patent Number 6,911,461; and (iii) the term “…assigns, is enjoined from infringing the Licensed Patent, on its own part or through
… 12 September 2023
1:20-cv-00987
835 Patent - Abbreviated New Drug Application(ANDA)
None |
External link to document |
2022-02-18 |
198 |
Notice of Service |
Salvatore Lepore Regarding Invalidity of U.S. Patent No. 6,911,461; and, (ii) Opening Expert Report of Samuel… 12 September 2023
1:20-cv-00987
835 Patent - Abbreviated New Drug Application(ANDA)
None |
External link to document |
2022-02-21 |
199 |
Notice of Service |
Objective Indicia of Non-Obviousness of U.S. Patent No. 6,911,461; (2) Opening Expert Report of David MacMillan…Non-Obviousness Supporting the Validity of U.S. Patent No. 6,911,461; and (3) Opening Expert Report of Tristan…Objective Indicia of Non-Obviousness of U.S. Patent No. 6,911,461 filed by UCB Biopharma SRL, UCB, Inc..(Dellinger… 12 September 2023
1:20-cv-00987
835 Patent - Abbreviated New Drug Application(ANDA)
None |
External link to document |
2022-04-08 |
200 |
Notice of Service |
Objective Indicia of Non-Obviousness of U.S. Patent No. 6,911,461 [CONFIDENTIAL]; and, (ii) Rebuttal Expert…Objective Indicia of Non-Obviousness of U.S. Patent No. 6,911,461 [CONFIDENTIAL] filed by Apotex Corp., Apotex… 12 September 2023
1:20-cv-00987
835 Patent - Abbreviated New Drug Application(ANDA)
None |
External link to document |